[go: up one dir, main page]

PL3504210T3 - 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych - Google Patents

7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych

Info

Publication number
PL3504210T3
PL3504210T3 PL17758527T PL17758527T PL3504210T3 PL 3504210 T3 PL3504210 T3 PL 3504210T3 PL 17758527 T PL17758527 T PL 17758527T PL 17758527 T PL17758527 T PL 17758527T PL 3504210 T3 PL3504210 T3 PL 3504210T3
Authority
PL
Poland
Prior art keywords
prophylaxis
treatment
virus infection
substituted
compounds
Prior art date
Application number
PL17758527T
Other languages
English (en)
Inventor
Lu Gao
Chungen Liang
Hongying Yun
Xiufang ZHENG
Jianping Wang
Kun MIAO
Bo Zhang
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3504210T3 publication Critical patent/PL3504210T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17758527T 2016-08-29 2017-08-28 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych PL3504210T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2016097140 2016-08-29
CN2017092653 2017-07-12
EP17758527.0A EP3504210B1 (en) 2016-08-29 2017-08-28 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
PCT/EP2017/071514 WO2018041763A1 (en) 2016-08-29 2017-08-28 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
PL3504210T3 true PL3504210T3 (pl) 2021-07-05

Family

ID=59738346

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17758527T PL3504210T3 (pl) 2016-08-29 2017-08-28 7-podstawione związki sulfonimidoilopurynonowe do leczenia i profilaktyki zakażeń wirusowych

Country Status (29)

Country Link
US (3) US10233184B2 (pl)
EP (2) EP3865482A1 (pl)
JP (2) JP7013467B2 (pl)
KR (2) KR20220147702A (pl)
CN (1) CN109641904B (pl)
AU (3) AU2017320742B2 (pl)
CA (1) CA3034148A1 (pl)
CL (1) CL2019000512A1 (pl)
CO (1) CO2019000932A2 (pl)
CR (1) CR20190087A (pl)
DK (1) DK3504210T3 (pl)
ES (1) ES2867849T3 (pl)
HR (1) HRP20210621T1 (pl)
HU (1) HUE053944T2 (pl)
IL (3) IL284255B (pl)
MA (1) MA46038B1 (pl)
MX (2) MX383500B (pl)
MY (1) MY197408A (pl)
PE (1) PE20190476A1 (pl)
PH (1) PH12019500432B1 (pl)
PL (1) PL3504210T3 (pl)
PT (1) PT3504210T (pl)
RS (1) RS61752B1 (pl)
RU (1) RU2751349C2 (pl)
SG (2) SG10202010520SA (pl)
SI (1) SI3504210T1 (pl)
TW (1) TWI671300B (pl)
UA (1) UA124270C2 (pl)
WO (1) WO2018041763A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
IL284255B (en) * 2016-08-29 2022-07-01 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
TWI720250B (zh) * 2016-09-13 2021-03-01 瑞士商赫孚孟拉羅股份公司 利用tlr7促效劑及hbv蛋白殼組裝抑制劑之組合治療
CN111699187A (zh) 2018-02-12 2020-09-22 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的砜化合物和衍生物
JP7089596B2 (ja) * 2018-02-28 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体
US20200113912A1 (en) 2018-09-12 2020-04-16 Silverback Therapeutics, Inc. Methods and Compositions for the Treatment of Disease with Immune Stimulatory Conjugates
MX2021009496A (es) 2019-02-08 2021-09-08 Progeneer Inc Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo.
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4115901A4 (en) 2020-03-02 2024-04-10 Progeneer Inc. Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022063278A1 (zh) * 2020-09-27 2022-03-31 上海维申医药有限公司 大环tlr7激动剂、其制备方法、药物组合物及其用途
GB202306325D0 (en) 2023-04-28 2023-06-14 Iksuda Therapeutics Ltd Antibody-drug conjugate compounds, and methods of use and treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485225D1 (de) * 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
AUPO912997A0 (en) * 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
ES2205573T3 (es) * 1997-11-28 2004-05-01 Sumitomo Pharmaceuticals Company, Limited Nuevo compuestos heterociclicos.
JPH11180981A (ja) * 1997-12-19 1999-07-06 Sumitomo Pharmaceut Co Ltd 複素環誘導体
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
WO2004006867A2 (en) * 2002-03-15 2004-01-22 Wayne State University 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents
MXPA05003193A (es) * 2002-09-27 2005-06-08 Sumitomo Pharma Compuesto de adenina novedoso y uso del mismo.
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
DE102006053049A1 (de) 2006-11-10 2008-05-15 Daimler Ag Staufach mit einer Abdeckeinrichtung
MX2009013832A (es) * 2007-06-29 2010-03-10 Gilead Sciences Inc Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
CA2745295C (en) * 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
SG10201406813RA (en) * 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
AU2015303558B2 (en) 2014-08-15 2018-07-12 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pyrrolopyrimidine compounds used as TLR7 agonist
NZ775222A (en) * 2015-05-08 2024-09-27 Hoffmann La Roche Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
IL284255B (en) * 2016-08-29 2022-07-01 Hoffmann La Roche 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
JP2019526633A (ja) 2019-09-19
KR102459155B1 (ko) 2022-10-28
AU2021204303B2 (en) 2022-05-12
PH12019500432A1 (en) 2019-10-21
AU2017320742B2 (en) 2021-08-05
US10233184B2 (en) 2019-03-19
MA46038B1 (fr) 2021-05-31
AU2017320742A1 (en) 2019-02-28
JP7013467B2 (ja) 2022-01-31
MX383500B (es) 2025-03-14
IL284255A (en) 2021-07-29
CR20190087A (es) 2019-04-30
CO2019000932A2 (es) 2019-02-08
CA3034148A1 (en) 2018-03-08
MY197408A (en) 2023-06-16
IL293475B2 (en) 2024-10-01
EP3865482A1 (en) 2021-08-18
HUE053944T2 (hu) 2021-08-30
JP2022050632A (ja) 2022-03-30
IL293475A (en) 2022-08-01
US20180072730A1 (en) 2018-03-15
HRP20210621T1 (hr) 2021-05-28
US20190256515A1 (en) 2019-08-22
SG11201901633WA (en) 2019-03-28
BR112019003519A2 (pt) 2019-05-21
RU2751349C2 (ru) 2021-07-13
RS61752B1 (sr) 2021-05-31
SG10202010520SA (en) 2020-11-27
ES2867849T3 (es) 2021-10-21
KR20220147702A (ko) 2022-11-03
CN109641904B (zh) 2022-01-28
DK3504210T3 (da) 2021-04-26
US20200385387A1 (en) 2020-12-10
UA124270C2 (uk) 2021-08-18
JP7214900B2 (ja) 2023-01-30
EP3504210B1 (en) 2021-02-24
IL284255B (en) 2022-07-01
CL2019000512A1 (es) 2019-07-12
KR20190039829A (ko) 2019-04-15
MA46038A (fr) 2019-07-03
AU2022204697A1 (en) 2022-07-21
TW201819382A (zh) 2018-06-01
WO2018041763A1 (en) 2018-03-08
RU2019107957A (ru) 2020-09-29
PH12019500432B1 (en) 2023-03-24
RU2019107957A3 (pl) 2020-12-18
PT3504210T (pt) 2021-04-19
IL293475B1 (en) 2024-06-01
PE20190476A1 (es) 2019-04-04
EP3504210A1 (en) 2019-07-03
IL264710B (en) 2021-07-29
MX2019002129A (es) 2019-06-20
AU2021204303A1 (en) 2021-07-22
NZ750604A (en) 2024-02-23
CN109641904A (zh) 2019-04-16
US10752630B2 (en) 2020-08-25
SI3504210T1 (sl) 2021-08-31
TWI671300B (zh) 2019-09-11
MX2021006902A (es) 2021-07-07

Similar Documents

Publication Publication Date Title
IL284255A (en) 7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection
IL246449B (en) Conjugated 6-heteroaryl dihydropyrimidines for the treatment and prevention of hepatitis b virus infection
IL280769A (en) New sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
ZA201901430B (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
ZA201507840B (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ZA201705634B (en) Quinoline derivatives for use in the treatment or prevention of viral infection
GB201615035D0 (en) Treatment and prevention of viral infection
HUE045242T2 (hu) Vírusfertõzések megelõzésére és terápiájára szánt ágens
ZA201900770B (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
LT3504210T (lt) Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection